Autologous exosomes in skin regeneration
AUTHOR:
dr Barbara Parda
Aesthetic & regenerative medicine doctor and psychiatrist
Mec Regenerate® – an intelligently programmed bioregeneration system designed to deliver long-term skin quality improvement. It is a next-generation biostimulator created in line with the philosophy of “less is more.” It supports gradual, biologically synchronized tissue renewal while respecting the skin’s natural regenerative rhythm. It represents a new level of balance between efficacy and safety. One of the first physicians to conduct observational studies on a Polish patient population is Dr. Barbara Parda-Głomska, a recognized expert in ultrasound-guided injection procedures. Here are her first impressions.
What is Mec Regenerate®?
Mec Regenerate® is a new skin bioregeneration product developed by the Italian company 303Pharma Srl, which holds a patent for recombinant collagen derived from silkworms.
This ingredient—already known from other breakthrough products on the market—has been combined with micronized medical-grade polycaprolactone (PCL), amino acids, and CMC. The result is a unique, cascade-based bioregeneration system aligned with the biological rhythm of the skin, delivering visible improvements in tissue quality, rejuvenation, firmness, and density.
Importantly, the product complies with the latest MDR requirements (currently in the final stage of certification, expected to be completed by the end of March 2026), confirming its high safety and efficacy profile.
Clinical evaluation on over 100 patients
Few aesthetic medicine products are tested on large patient groups at the time of launch. 303Pharma is conducting clinical and histopathological studies in Italy.
In Poland, as many as 11 centers—including the practice of Dr. Barbara Parda-Głomska—are participating in observational studies and documentation of results. In the UK, one center is involved.
A total of 103 patients will undergo a recommended series of two treatments spaced 60 days apart (with a possible third session after 6 months if indicated). Results will be documented, evaluated by both physicians and patients, and shared with professionals.
What differentiates Mec Regenerate® from other stimulators?
Mec Regenerate® does not aim to deliver an immediate volumizing effect. It is also not a strong volumizing biostimulator.
Instead, it initiates a controlled, multi-stage dermal reconstruction process, optimizing the tissue’s ability to rebuild collagen and elastin networks over time. This ensures a safe, predictable, and natural outcome, without altering facial features.
Advanced four-component formula
The patented formula developed by 303Pharma is based on four key components:
Recombinant type I collagen alpha-1 chain (Alpha-1 Concept)
Produced by silkworms using a human collagen gene, it is 99.9% identical to human collagen. Highly bioavailable, non-immunogenic, non-allergenic, and non-pathogenic. It activates regenerative signaling, stimulates fibroblasts to produce new collagen, and supports extracellular matrix renewal—restoring firmness, density, and skin structure.
Medical-grade polycaprolactone (PCL)
In the form of a micronized, injectable, water-soluble powder, it ensures high biocompatibility and safety while minimizing adverse reactions associated with other PCL-based products. After injection, PCL microspheres create a temporary scaffold. As they gradually biodegrade, they stimulate fibroblasts to produce endogenous collagen, improving skin firmness and elasticity over time.
Amino acids (Pro-Elastin complex)
A balanced blend of glycine, proline, valine, and alanine—key to elastin biosynthesis and fibroblast activity. This complex supports extracellular matrix reconstruction and improves biomechanical skin properties such as elasticity, resilience, and tension.
Carboxymethylcellulose (CMC)
A safe, biocompatible polysaccharide used as a hydrogel carrier. It ensures smooth injection and even distribution within tissues, facilitating long-term biostimulatory action. Due to its hygroscopic properties, it also provides hydration. It is resorbed within a few weeks, giving way to the long-term regenerative effects of PCL.
A system, not just a combination
Mec Regenerate® is not simply a blend of ingredients—it is a carefully designed, clinically validated system. Each component is delivered in physiological doses and activates at the appropriate biological phase following injection, triggering a cascade of tissue repair processes.
The synergy between early bioactive release and gradual PCL degradation enables both immediate skin quality improvement and long-term structural regeneration.
Treatment timeline and effects
0–7 days – Hydration and subtle filling
Improved skin turgor, firmness, mild volumization, and a healthy glow.
1–4 weeks – Collagen remodeling
Enhanced elasticity, smoother texture, and reduction of fine lines.
1–3 months – Onset of biostimulation
Restored volume, reduction of deeper wrinkles, and improved definition of the jawline and cheeks.
3–24 months – Long-term regeneration
Sustained lifting effect, increased dermal density, and overall skin quality improvement. The non-volumizing nature of PCL minimizes the risk of post-procedural swelling.
Histopathological findings confirm:
- Extracellular matrix restructuring, including collagen type I and elastin remodeling
- Progressive lifting and volumizing effects due to fibroblast stimulation
- Improved skin elasticity and firmness, ensuring natural, long-term aesthetic outcomes while preserving facial harmony during the aging process
Mec Regenerate® – regeneration under ultrasound guidance
Mec is a system with a unique composition of ingredients which, for the purposes of optimizing outcomes and ensuring procedural safety, we recommend administering under ultrasound guidance. As no antidote exists for fillers other than hyaluronic acid, it is advisable to utilize widely available injection visualization techniques to ensure precision, predictability of results, and overall treatment safety.
The currently registered formulation, Mec Regenerate®, is intended for the regeneration of lax facial skin, and according to the treatment protocol, injections are recommended in the midface and lower face areas. The use of ultrasound enables precise placement of the product within the appropriate tissue layer and helps avoid unintended injections into structures such as the parotid gland, masseter muscle, or the SMAS.
In the ultrasound examination (figure below), within the subcutaneous layer, a longitudinal, homogeneous, mass-like hypoechoic structure can be observed, clearly demarcated from the surrounding subcutaneous tissue. Mec Regenerate® is deposited in the subcutaneous tissue, above the parotidomasseteric fascia (SMAS), where it distributes harmoniously between the delicate structures of the retinacula cutis.
Based on my initial clinical experience and in accordance with the innovator’s protocol, it is recommended to administer the product using a 22G cannula, slowly, while observing the behavior of the product within the tissues. The ampoule contains 1.8 ml of Mec Regenerate® and is uniquely marked at the midpoint of its volume, allowing full control over the amount administered. A dose of 0.1 ml per cannula pass is recommended, enabling safe and precise fanning injections into the subcutaneous tissue of the treated area. Entry points should be selected individually by the practitioner based on their experience—commonly, the preauricular area is chosen. Similarly, the length of the 22G cannula depends on the treated area—38 mm, 50 mm, or 70 mm.
Based on my observations, the clinical effect is visible immediately after the procedure and is often spectacular. Even after treating one side of the face, a clear improvement in skin quality, firmness, and overall condition can be observed, which is highly appreciated by patients.
